Development of a genome-wide CRISPR Screen in CD4+ T Cells to Identify Drug Targets for Immune-mediated Inflammatory Diseases

GTx

Transfect up to 20 billion cells with our clinically validated and cGMP compliant Flow Electroporation^®.

ATx

From small to medium static Electroporation.

VLx

For gram scale protein production.

STx

Transfect up to 20 billion cells with scalable static or Flow Electroporation^®.

Discover scalable engineering to enable safe and potent cell therapies.

Navigate the complexities of genome engineering with highly efficient delivery.

Accelerate biotherapeutic development with transient expression for gram-scale protein production.

Produce assay-ready cells faster with scalable electroporation.

Transfect adherent or suspension cells to produce a variety of viral vectors.

Innovate vaccine research with our adaptable platform for production of recombinant proteins, virus-like particles.

Industries

Partnering with developers to accelerate development and scale cell therapy programs toward clinical success.

Accelerating breakthrough discoveries with high-efficiency, reproducible electroporation across cell types.

Enabling efficient, reproducible transfection in virtually any cell type for high-yield transient expression and rapid cell line development.